Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2015)
✉ Email this page to a colleague
AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-05-27 |
| Court | District Court, N.D. West Virginia | Date Terminated | 2017-10-05 |
| Cause | 35:271 Patent Infringement | Assigned To | Irene Patricia Murphy Keeley |
| Jury Demand | None | Referred To | |
| Parties | ASTRAZENECA UK LIMITED | ||
| Patents | 8,431,154; 8,536,206; 8,604,064; 8,618,142 | ||
| Attorneys | Gordon H. Copland | ||
| Firms | Wilmer Cutler Pickering Hale & Dorr LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca AB v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-10-05 | 24 | Page 3 of 12 PageID #: 281 U.S. Patent No. 8,431,154 (the “’154 patent”), which, at present, has not been…Plaintiffs’ U.S. Patent Nos. 5,712,298 (the “’298 patent”), 8,536,206 (the “’206 patent”), 8,604,064 (the…(the “’064 patent”), 8,618,142 (the “’142 patent”). Plaintiffs sell roflumilast tablets under the tradename…claims of the ’298, ’206, ’064, and ’142 patents, and that the patents are invalid. Additionally, Mylan has… ’206, ’064,’142, and ’154 patents are referred to herein as the “patents-in-suit.” | External link to document | |
| 2015-10-09 | 26 | x27;206 patent," as used herein, refers to and includes United States Patent No. 8,536,206, titled… of, or all of United States Patent Nos. 5,712,298, 8,431, 154, 8,536,206, 8,604,064, and 8,618,142. …matter of the patents-in-suit or any patents or patent applications related to the patents-in-suit, and… The phrase "patents or patent applications related to the patents-in-suit" means every…enforcement or defense of any patent-in-suit or any related patent or patent application, and identification | External link to document | |
| 2015-11-11 | 40 | 2) correct the expiration dates of U.S. Patent Nos. 8,536,206; 8,604,064; 8,618,142 and the thirty month…2020 • U.S. Patent Nos. 8,536,206; 8,604,064; 8,618,142: March 8, 2024 Thirty Month…U.S. Patent No. 5,712,298 to reflect a patent term extension granted by the United States Patent and …2015 Date of Expiration of Patents: • U.S. Patent No. 5,712,298: January 27, 2020 … Amended Supplemental Information for Patent Cases Involving An Abbreviated New Drug Application | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
